From Name:
From Email:
To Name:
To Email:

Optional Message:


FDA approves Praxbind, the first reversal agent for anticoagulant Pradaxa

from U.S. Food and Drug Administration

The U.S. Food and Drug Administration granted accelerated approval to Praxbind (idarucizumab) for use in patients who are taking the anticoagulant Pradaxa (dabigatran) during emergency situations when there is a need to reverse Pradaxa's blood-thinning effects. The FDA approved Pradaxa in 2010 to prevent stroke and systemic blood clots in patients with atrial fibrillation, as well as for the treatment and prevention of deep venous thrombosis and pulmonary embolism. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063